LRP1 and central nervous system cancer: In this context, dual conjugation of Angiopep-2, exhibiting high LRP1 binding efficiency, and TAT, providing glioma targeting function, to liposomal formulation (DOX-TAT-Ang-LIP) enhanced brain penetration in vitro.